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Abstract
This concise review attempts to highlight the recent advances in magnetic resonance imaging (MRI) in
relation to all the different aspects of prostate cancer (PCa), and outlines future implications of MRI in
the diagnosis, treatment, and surveillance of PCa.
Introduction and context
Prostate cancer (PCa) is the most common malignancy
in men – around 200,000 new cases were diagnosed in
the US in 2009 – and is responsible for the highest rate of
malignancy related mortality after lung cancer [1].
Currently, trans-rectal ultrasound-guided biopsy
(TRUS-Bx) is the ‘gold standard’ for diagnosis of PCa.
However, TRUS-Bx can lead to serious infections and
urosepsis, reported in at least 2-4% of patients [2].
Upon diagnosis of PCa, management decisions pose a
dilemma for both the patient and physician. Despite the
Scandinavian Prostate Cancer Group Study [3,4] and the
European Randomized Study of Screening for Prostate
Cancer [5] providing evidence of a reduction in disease-
specific mortality in screened and treated PCa popula-
tions, it is estimated that between 25 and 84% of PCa
patients currently being treated will not succumb to their
disease should they be left untreated, in other words, they
have a clinically insignificant form of the disease [4,6-10].
Therefore, a sensitive and specific enough imaging moda-
lity is needed to help discern between patients with
insignificant diseaseand the patientsin needoftreatment,
anditmightalsoalleviatetheneedforbiopsiestobetaken
for accurate diagnosis, or at least significantly lower the
number of biopsy cores needed.
One such modality is magnetic resonance imaging (MRI),
which has been used to evaluate prostate anatomy and
prostate diseases since 1982 [11]. MRI is able to provide
detailed anatomical images, particularly of soft tissues, at
high spatial resolution, and when combined with the
ability to provide functional measurements has lead
investigators to extensively explore the role of MRI in
diagnosis and staging of PCa. Different sequences (the
manner in which the magnet creates pulses and interfaces
with the data collected) have been manipulated and even
combined to give the greatest information (e.g., contrast-





(T2W) imaging to visualize the anatomy and the
architecture of the prostate gland. PCa may be seen as
an area with low signal intensity; however, several benign
conditions,suchasprostatitis,intra-prostatic hemorrhage,
and scarring, have a similar appearance, therefore this
method has a relatively low specificity of 54-82% and a
widely varied sensitivity of 46-96% [12-14]. However, in
addition to anatomic information, MRI can elucidate
physiological properties of tissue through different
imaging techniques such as diffusion-weighted MRI
(DW-MRI), which measures the diffusion of water
molecules in tissue. Due to its increased cellular density,
PCa shows restricted diffusion. Dynamic contrast-
enhanced MRI (DCE-MRI) is another technique that
assesses the microvascular properties of tissue. As PCa has
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Finally, magnetic resonance spectroscopic imaging
(MRSI) can be used to measure metabolite levels in the
tissue, particularly choline, citrate, creatine, and various
polyamines. PCa usually exhibits an increased concentra-
tion of choline, a reduction of citrate, and lower levels of
polyamines. Creatine is usually unaffected.
Each imaging technique has been tried separately and
been shown to improve PCa localization and detection,
but much more interesting is the recent usage of
the different modalities in combination, such as multi-
parametric MRI scanning, which has an improved
specificity and sensitivity. Recently, Kitajima et al. [15]
reported a specificity of 95% and sensitivity of 80% using
3 telsa (3T) MRI and multiparametric scanning. These
results have been repeated in many similarly designed
trials [16,17].
Tumor volume
In addition to resolving the tumor location, assessing the
tumor volume might help with decisions related to the
management of the tumor. There is a large variability
and generally a poor correlation between MRI-measured
tumor volumes and pathologic-examination tumor
volume using conventional T2W imaging [18,19]. How-
ever, combining different imaging techniques has been
shown to significantly increase the accuracy of MRI-
calculated tumor volume [19,20]. It is now possible to
delineate the tumor with accuracy using MRI, providing a
‘safety margin’ of 5 mm is maintained [21]. (The safety
margin is the rim outside the delineated tumor volume
neededtobetreatedinordertoavoidleavingviabletumor
cells.) Delineating tumors allows for targeted therapies to
be implemented.
Tumor aggressiveness
Tumor biology as currently graded by the Gleason score
is one of the key prognostic factors of PCa patients
[22,23]. In order to achieve accurate grading one must
attain a tissue sample by biopsy. Yet even today, despite
more cores being taken per biopsy session, there are still
often discrepancies between biopsy samples and final
histopathology reports [24].
MRSI is a noninvasive diagnostic tool to assess cancer
metabolism and elucidate its biological propensities
[25-27]. There is enough evidence to suggest that by
using MRSI, risk criteria can be assigned for PCa patients
even more accurately than with the Gleason grade
determined using TRUS-Bx [28,29]. However, larger
studies in multiple centres are required to confirm this
observation.
MRI guidance for prostate biopsies
TRUS-Bx, which is currently the ‘gold standard’ for PCa
detection, relies on random sampling of the prostate
[30], hence the recent trend for a greater number of core
biopsies being taken per patient in order to increase the
detection of PCa [31-33]. This can be partly avoided,
however, by using lesions that appear suspicious on
MRI to direct TRUS-Bx. This has been shown to greatly
improve PCa detection in patients with prior negative
biopsy and suspicion of harbouring malignancy [34-37].
MRI-guided biopsies have also been performed [38-42]
but only limited data is available thus far regarding their
efficacy and no trial has compared MRI-guided prostate
biopsies with TRUS-Bx.
MRI-guided prostatic interventions
MRI has been used to guide and monitor ablations in a
variety of tumors [43-47] including in PCa [48]. In fact,
MRI has also been utilized to accurately place high-dose-
rate brachytherapy rods [49,50].
MRI has the uniquecapability tomeasure the temperature
distribution in the prostate gland continuously during
thermal ablative treatment to enable delivery of adaptive
therapy. This continuous monitoring can be used to
compensate for changes in blood flow, prostate size, and
minor prostate movement. In addition, quantitative
knowledge of the amount of heating in surrounding
tissues can be used to protect these regions from thermal
damage.
Chen et al. [51] performed MRI-guided percutaneous
interstitial microwave thermoablation of locally recur-
rent PCa. MRI-derived temperatures were linearly related
to the tissue temperatures, measured with an MRI-
compatible thermosensor, therefore they concluded that
MRI can be used to guide thermoablation. Chopra et al.
showed that using MRI thermometry while applying
trans-urethral MRI-guided high intensity-focused ultra-
sound (HIFU) allowed for stable temperature measure-
ments, which were achieved with a standard deviation of
approximately ±1ºC [52].
Assessment of treatment effects and recurrent disease
Afterdifferenttreatmentshavebeenconductedthataimto
destroy the tumor and leave the prostate behind (such as
external beam radiationandfocal therapy), itisimportant
to accurately assess the ablation size and validate that it
encompassed the desired pre-treatment ablation area, as
well as to diagnose disease recurrence.
In order to evaluate the ability of MRI to accurately define
ablationvolume,Djavanetal.[53]utilizedradiofrequency
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good correlation between MRI-calculated volume and
volume calculated using hematoxylin and eosin (H&E)
stains. Larson et al. [54] found a strong correlation (r =
0.92) between MRI volumetric assessment of damage and
H&E assessment of damage when using different mini-
mally invasive treatment modalities to create intrapro-
static lesions.
Far more recent studies have shown that MRI is a pro-
mising imaging biomarker for therapeutic response of
PCa to radiotherapy [55] and allows detection of PCa
recurrence after external radiation therapy treatment
[56,57] or HIFU treatment [58].
Local persistence or progression after radical prostatect-
omy is a major reason why prostate-specific antigen(PSA)
levels may still be elevated after treatment [59,60]. TRUS
of the prostatic fossa in association with TRUS-Bx is
considered more sensitive than a digital rectal examina-
tion for detecting local recurrence, especially if PSA levels
are low [61]. However, TRUS is unlikely to detect tumor
massat low PSA levels (<1ng/ml) and the role ofa biopsy
remains unclear,specifically,whether there isreallyaneed
to take a biopsy in the event of PSA failure.
Accurate identification of local recurrence with pelvic
imaging might improve the effectiveness of tumor
eradication with radiotherapy, as MRI has been shown
to identify residual disease even when low PSA levels have
been detected [62,63]. It seems that DCE imaging further
improves the ability to detect local recurrence in patients
at high risk of post-prostatectomy failure [64,65].
Active surveillance and MRI
To combat potential overtreatment of clinically insignif-
icant cancer, active surveillance has emerged as an
alternative management strategy [66]. Patients who are
suspected of having insignificant PCa based on physical
examination, PSA levels,and TRUS-Bxresults (comprising
Gleason score, the number of positive cores, and the
percentage of core infiltrated by tumour) are actively
monitored. Should the suspicion arise that the disease is
progressingor‘active’(asopposedtoinsignificantdisease)
based on PSA (rise or kinetics), rectal examination, and
repeat biopsies, the patient would undergo curative whole
gland treatment. This scheme offers curative treatment to
patients we believe warrant it while avoiding inflicting
unwarranted side effects on patients who do not need
treatment (due to an insignificant disease) [66].
van As et al. [67] analysed the apparent diffusion
coefficient (ADC) generated from DW-MRI with respect
to repeat biopsy findings and time to radical treatment in
86 patients in a prospective study of active surveillance.
They demonstrated that a low ADC is associated with
adverse histology on repeat biopsy and shorter time to
deferred radical treatment. Tumor ADC was highly and
significantly correlated with maximum core involve-
ment, percentage of positive cores, and the ratio of free/
total PSA. Tumor ADC was also significantly correlated
with initial PSA level, but not with PSA velocity.
In a recent retrospective study, Fradet et al.[ 6 8 ]
demonstrated that patients with lesion findings sugges-
tive of PCa on MRI were at a higher risk for Gleason score
upgrading on a subsequent prostate biopsy.
Implications for clinical practice
MRI is fast becoming a multipurpose imaging modality
and might soon change the way we think and treat PCa.
It is quite plausible that, in the near future, patients who
are suspected of harbouring PCa due to elevated serum
markers (PSA, PCA3 [prostate cancer antigen 3], or
others) will undergo an MRI scan and, according to the
results, will either be told all is well or go on an active
surveillance protocol, undergo an MRI-guided focal
ablation, or go through radical treatment. It stands to
reason that the follow-up regimen will consist of
biomarker detection and MRI scans; however, currently,
the role of MRI is still limited and not well defined by
clinical guidelines.
The authors use this imaging tool mostly in patients who
have had a previous negative biopsy and are suspected of
harbouring PCa, and in prospective studies of patients
who are candidates for an active surveillance protocol.
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